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Abstract
Introduction Activation of the type I insulin-like growth factor
receptor (IGFIR) promotes proliferation and inhibits apoptosis in
a variety of cell types. Transgenic mice expressing a
constitutively active IGFIR or IGF-I develop mammary tumors
and increased levels of IGFIR have been detected in primary
breast cancers. However, the contribution of IGFIR activation in
promoting breast cancer progression remains unknown.
Mammary epithelial cell lines grown in three-dimensional
cultures form acinar structures that mimic the round, polarized,
hollow and growth-arrested features of mammary alveoli. We
used this system to determine how proliferation and survival
signaling by IGFIR activation affects breast epithelial cell biology
and contributes to breast cancer progression.
Methods Pooled, stable MCF-10A breast epithelial cells
expressing wild-type IGFIR or kinase-dead IGFIR (K1003A)
were generated using retroviral-mediated gene transfer. The
effects of over-expression of wild-type or kinase-dead IGFIR on
breast epithelial cell biology were analyzed by confocal
microscopy of three-dimensional cultures. The contribution of
signaling pathways downstream of IGFIR activation to
proliferation and apoptosis were determined by
pharmacological inhibition of phosphatidylinositol 3' kinase
(PI3K) with LY294002, MAP kinase kinase (MEK) with UO126
and mammalian target of rapamycin (mTOR) with rapamycin.
Results We found that MCF-10A cells over-expressing the
IGFIR formed large, misshapen acinar structures with filled
lumina and disrupted apico-basal polarization. This phenotype
was ligand-dependent, occurring with IGF-I or
supraphysiological doses of insulin, and did not occur in cells
over-expressing the kinase-dead receptor. We observed
increased proliferation, decreased apoptosis and increased
phosphorylation of Ser473 of Akt and Ser2448 of mTOR
throughout IGFIR structures. Inhibition of PI3K with LY294002
or MEK with UO126 prevented the development of acinar
structures from IGFIR-expressing but not control cells. The
mTOR inhibitor rapamycin failed to prevent IGFIR-induced
hyperproliferation and survival signaling.
Conclusion Increased proliferation and survival signaling as
well as loss of apico-basal polarity by IGFIR activation in
mammary epithelial cells may promote early lesions of breast
cancer. Three-dimensional cultures of MCF-10A cells over-
expressing the IGFIR are a useful model with which to study the
role of IGFIR signaling in breast cancer progression and for
characterizing the effects of chemotherapeutics targeted to
IGFIR signaling.
Introduction
Cycles of proliferation and invasion followed by massive apop-
tosis are central to the physiology of the mammary gland. The
branching ductal architecture develops postnatally in
response to hormone stimulation during puberty, but does not
reach a fully differentiated state until pregnancy and lactation
when hormones stimulate the proliferation and differentiation
of terminal ductal lobular units that contain many alveoli. Fol-Page 1 of 13
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Breast Cancer Research    Vol 8 No 2    Yanochko and Eckhart lowing lactation, the mammary gland undergoes massive
apoptosis and returns to its pre-pregnancy state, a process
called involution. Insulin-like growth factor (IGF) signaling is
essential for these processes.
Activation of the type I insulin-like growth factor receptor
(IGFIR), by binding of IGF-I or supraphysiological doses of
insulin, results in receptor autophosphorylation, association
and phosphorylation of adapter proteins such as insulin recep-
tor substrate (IRS)-I, Shc, Crk, Grb-2, and Grb-10, and subse-
quent activation of downstream signaling pathways, including
phosphatidylinositol 3' kinase (PI3K)/Akt and Ras/Raf/
mitogen-activated protein kinase (MAPK). Activation of the
IGFIR leads to proliferation and anti-apoptotic signaling in a
variety of cell lines [1,2]. Embryonic mammary buds trans-
planted from IGFIR knockout mice into syngeneic recipients
showed decreased proliferation of cap cells in terminal end
buds and decreased branching and extension of ducts into the
fat pad [3]. Similarly, IGF-I knock-out mice have fewer terminal
end buds and decreased ductal branching [4,5].
Several lines of evidence suggest that the IGFIR is involved in
breast cancer progression: breast cancer cell lines express
the IGFIR [6]; transgenic mice over-expressing a constitutively
active IGFIR develop mammary tumors at an early age [7];
transgenic mice expressing a truncated IGF-I, with decreased
affinity for IGF binding proteins, have increased incidence of
spontaneous mammary tumors, and tumors appear earlier
when combined with p53 mutation [8,9]. IGFIR expression is
regulated by transcription factors such as p53 and the estro-
gen receptor that are mutated in or associated with breast
cancer [10-12]. Administration of IGFIR antisense oligonucle-
otides decreased mammary tumor growth in a mouse model of
mammary carcinogenesis [13]. Expression of a dominant neg-
ative IGFIR inhibited adhesion and invasiveness of breast can-
cer cell lines and metastases in vivo [14]. Epidemiological
studies correlate increased serum IGF-I levels and insulin-like
growth factor binding proteins with increased risk of breast
cancer [15,16], and increased levels of IGFIR have been
found in human breast cancer specimens, although the gene
is rarely amplified [17-19]. In addition, the oncogenic activity
of IGFIR is well established: NIH3T3 cells expressing IGFIR
form colonies in soft agar and induce tumors when trans-
planted into nude mice [20]. In addition to the receptor, many
components of the IGF system have been implicated in breast
cancer through epidemiological or cell culture studies [21,22].
Despite this evidence, the contribution of proliferation and sur-
vival signaling resulting from IGFIR activation to promote early
stages of breast cancer is not well understood. Three-dimen-
sional cultures of mammary epithelial cells form in vitro struc-
tures with features similar to those of alveolar units of the
mammary gland, such as spheroid shape, proliferative arrest,
hollow lumen, apico-basal polarity and secretion of basement
membrane proteins. Retention of physiological features of the
mammary gland while simplifying dissection of the molecular
pathways controlling proliferation, apoptosis and extracellular
matrix interaction and their alterations by oncogenes make
three-dimensional cultures of breast epithelial cells an attrac-
tive model to study IGFIR signaling and the processes
involved in forming early breast cancer lesions [23-25]. A
recent paper by Irie and colleagues [26] demonstrated the iso-
form specific contribution of Akt to IGFIR acinar structure for-
mation (see Discussion). Here, we demonstrate that IGFIR
expression in MCF-10A breast epithelial cells leads to altera-
tions in acinar morphology reminiscent of early stages of
breast cancer, namely enlarged, misshapen, filled acinar struc-
tures that result from loss of apico-basal polarity and increased
proliferation and survival signaling. Inhibition of downstream
signaling pathways with UO126 or LY294002 but not
rapamycin disrupted IGFIR acinar development.
Materials and methods
Cell culture and reagents
MCF-10A cells were obtained from the American Type Tissue
Culture Collection and cultured in F12/DMEM (Gibco, Invitro-
gen Corp., Carlsbad, CA, USA) with 5% horse serum (Gibco),
5 ng/ml epidermal growth factor (Research Diagnostics, Inc.,
Concord, MA, USA), 10 µg/ml insulin (Research Diagnostics,
Inc.), 0.1 µg/ml cholera toxin (Calbiochem, San Diego, CA,
USA), 0.5 µg/ml hydrocortisone (Sigma, St. Louis, MO, USA)
and penicillin/streptomycin (Gibco). Growth factor reduced
Matrigel (BD Biosciences, San Jose, CA, USA) with protein
concentrations between 10 and 12 mg/ml was used. IGF-I
was from Research Diagnostics, Inc. LY294002 (2-(4-Mor-
pholinyl)-8-phenyl-4H-1-benzopyran-4-one), rapamycin, and
UO126 (1,4-Diamino-2,3-dicyano-1,4-bis(2-aminophe-
nylthio)butadiene) were from Calbiochem. Antibodies to the
carboxyl terminus of the β-subunit of the IGFIR were described
previously [27]; extracellular-signal regulated kinase (ERK)2,
p70S6 kinase (p70S6K1) and IRS-1 were from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA, USA); phospho-Akt
(Ser473), phospho-Akt (Ser473 Immunohistochemistry spe-
cific), Akt, phospho-mammalian target of rapamycin (mTOR;
Ser2448) and cleaved caspase-3 (Asp175) were from Cell
Signaling (Beverly, MA, USA); phospho-ERK1/2 and α-tubulin
were from Sigma; laminin V (γ2 chain) was from Chemicon
International (Temecula, CA, USA); E-cadherin and Golgi
matrix protein of 130 kDa (GM130) were from BD Transduc-
tion Laboratories (Franklin Lakes, NJ, USA; Ki-67 was from
Zymed Laboratories (San Francisco, CA, USA); and phospho-
p70S6K1 (Thr389) was from Upstate (Charlottesville, VA,
USA). Fluorescently labeled secondary antibodies for immu-
noblotting were Alexa fluor 680 goat anti-mouse IgG (Molecu-
lar Probes, Invitrogen Corp, Carlsbad, CA, USA) and
IRDye800 donkey anti-rabbit IgG (Rockland Immunochemi-
cals, Inc., Gilbertsville, PA, USA).Page 2 of 13
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pCLXSN and pCLXSN containing the human IGFIR were
described previously [27]. Kinase-dead IGFIR construct
(K1003A) was generated by QuickChange (Stratagene, La
Jolla, CA, USA) site-directed mutagenesis using the following
primers (mutations in bold): sense, 5'-cctgaaaccagagt-
ggccattgcaacagtgaacgag-3'; antisense, 5'-ctcgttcactgtt-
gcaatggccactctggtttcagg-3'. Pooled, stable MCF-10A cell
lines expressing the wild-type IGFIR or K1003A were gener-
ated using retroviral-mediated gene transfer followed by selec-
tion with G418 (400 µg/ml). Transfection of retroviral
constructs and vesicular stomatitis virus glycoprotein (VSVG)
into human embryonic kidney (HEK)293 cells stably express-
ing gag and pol produced VSVG pseudotyped retroviruses.
Viral supernatant was collected, filtered, supplemented with
polybrene (4 µg/ml; Sigma-Aldrich, St. Louis, MO, USA) and
added to MCF-10A cells plated at 5 × 105 cells/10 cm plate
the day before infection.
Figure 1
MCF-10A cells over-expressing the type I insulin-like growth factor receptor (IGFIR) form large, misshapen, filled acinar structures. (a) Differential 
interference contrast images of acinar structures formed from stable pools of MCF-10A cells infected with virus expressing empty vector (pCLXSN; 
upper panels) or wild-type IGFIR (lower panels) after 8, 15 and 20 days of growth. Scale bars = 50 µm. (b) Equatorial confocal sections of corre-
sponding images in (a). Control (pCLXSN; upper panels) and IGFIR structures (lower panels) were labeled with the nuclear counterstain TO-PRO-3 
after 8, 15 and 20 days of growth in three-dimensional culture. Scale bars = 50 µm.Page 3 of 13
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Whole-cell lysates were prepared from monolayer cultures
after rinsing cell layers two times with PBS followed by lysis in
NP40 buffer (1% NP40, 40 mM Hepes pH 7.5, 120 mM NaCl,
1 mM EDTA, 10 mM pyrophosphate, 10 mM glycerophos-
phate, 50 mM NaF) supplemented with phenylmethylsulfonyl
fluoride, dithiothreitol, and leupeptin just prior to use. Lysates
were cleared by centrifugation for 30 minutes at 12,000 rpm
at 4°C. Supernatants were collected and Laemmli buffer was
added to each sample. Proteins resolved by SDS-PAGE were
transferred to Immobilon-FL polyvinylidene fluoride (PVDF; Mil-
lipore, Billerica, MA, USA) by semi-dry transfer. Membranes
were blocked for 1 hour with 0.1% casein in 0.2× PBS fol-
lowed by incubation with primary antibodies overnight at 4°C.
Secondary antibodies were fluorescently labeled for visualiza-
tion with an Odyssey infrared imaging system (LI-COR Bio-
sciences, Lincoln, NE, USA).
Immunoblotting (three-dimensional cultures)
Acinar structures were grown on Matrigel in 35 mm plates.
After 16 days of growth, acinar structures were isolated from
Matrigel with cold 0.02% EDTA and shaking for 1 hour at 4°C.
IGFIR-10A cells isolated from Matrigel were pelleted by cen-
trifugation and lysed as above. Lysates immunoprecipitated
with antibodies to p70S6K were separated by SDS-PAGE,
transferred to PVDF and immunoblotted with antibodies to
p70S6K or phospho-specific antibodies to p70S6K- [T389].
Morphogenesis assay
Three-dimensional cultures of MCF-10A cells were grown in
8-well chamber slides (Falcon) as described [28] using
growth factor reduced Matrigel (BD Biosciences) with protein
concentration between 10 and 12 mg/ml. Except where indi-
cated, assay medium (F12/DMEM, supplemented with 2%
horse serum, 0.5 µg/ml hydrocortisone, 0.1 µg/ml cholera
toxin, 2% Matrigel, 5 ng/ml epidermal growth factor, 10 µg/ml
insulin or 10, 50 or 100 ng/ml IGF-I, pen/strep) was changed
every 3 to 4 days. Inhibitors were added after allowing acinar
development to progress for three days. Growth medium con-
taining inhibitors was replaced every 2 to 3 days.
Immunofluorescence analysis and image acquisition
MCF-10A acinar structures were immunolabeled as described
[28] with the following modifications: permeabilization with
0.5% Triton X-100 was performed for 30 to 40 minutes at
room temperature to avoid Matrigel solubilization at 4°C.
Nuclei were counterstained with TO-PRO-3 iodide (TO-PRO-
3; Molecular Probes) prior to mounting with Gel/Mount
(biømeda, Foster City, CA, USA) or Pro-Long Gold Antifade
(Molecular Probes). Images were obtained with a Zeiss LSM
5 scanning confocal microscope or a Leica SP2 AOBS con-
focal microscope, converted to JPEG (Zeiss LSM 5 images)
and arranged using Adobe Photoshop 7.0.
Results
During the initial phases of MCF-10A acinar development
(days 0 to 4) a single cell plated on basement membrane
(Matrigel) progresses to a cluster of cells at which time polar-
ization and survival signaling in cells in contact with basement
membrane drive the formation of a polarized outer layer of
cells. Apoptosis and autophagy clear the inner cells, those that
lack contact with the basement membrane, to generate a hol-
low, polar, growth arrested structure by approximately day 10
[29-31]. To study the effects of IGFIR activation on acinar mor-
phogenesis, stable pools of MCF-10A cells expressing the
wild-type human IGFIR or empty vector, pCLXSN (hereafter
called control), were generated by retroviral infection. Figure 1
shows differential interference contrast (DIC) and confocal
sections of control and IGFIR structures after 8, 15 and 20
days. Nuclei were labeled with the nuclear stain TO-PRO-3.
Consistent with results reported previously [29,30], control
cells form round acinar structures that have reached their max-
imal size by day 8. Luminal cells are observed in control struc-
tures at day 8, but by day 15, control structures had hollow
lumina, a feature that was retained with successive days in cul-
ture (Figure 1b). In contrast, although IGFIR structures appear
round after 8 days of acinar development, they are larger than
the control structures. By day 15, IGFIR structures are notice-
ably misshapen (Figure 1a) and, unlike control structures,
there is no noticeable lumen formation (Figure 1b). The IGFIR
structures remain large, misshapen and filled even when cul-
tured up to 40 days (data not shown). These results were con-
firmed with three independently derived stable pools of cells
and three lots of Matrigel.
To test whether these phenotypes were dependent on the pro-
tein kinase activity of IGFIR, we generated stable pools of
MCF-10A cells expressing a kinase-dead IGFIR construct,
with lysine 1003 in the ATP-binding site mutated to alanine
(K1003A) [32]. Figure 2a shows DIC images and confocal
sections through control, K1003A and IGFIR structures after
20 days in three-dimensional culture grown in the standard
three-dimensional growth medium (see Materials and meth-
ods), which contains 10 µg/ml insulin (Figure 2a, panels a, c,
d, f, g, i) or with 100 ng/ml IGF-I substituted for insulin (Figure
2a, panels b, e, h). At 10 µg/ml (about 2 µM), insulin is acting
through the IGFIR. While IGF-I, insulin or IGF-II can activate
the IGFIR, the affinity of IGF-I for the IGFIR is three-fold greater
than that of insulin or IGF-II [33,34]. Whether cultured in the
presence of insulin or IGF-I, control structures were small and
round (Figure 2a, panels a, b). Regardless of activation by
insulin (Figure 2a, panel g) or IGF-I (Figure 2a, panel h), wild-
type IGFIR structures were large and misshapen while
K1003A structures had the small, round appearance of con-
trol structures. Confocal cross-sections of acinar structures
labeled with antibodies to the IGFIR and the nuclear counter-
stain TO-PRO-3 (Figure 2a, panels c, f, i) showed that, unlike
control, IGFIR structures had filled lumina (Figure 2a, panel i),
similar to structures formed from MCF-10A cells over-express-Page 4 of 13
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(CSF1R) or human growth hormone [29,30,35,36]. K1003A
structures formed lumina and only the smallest structures had
detectable IGFIR expression (Figure 2a, panel f). As expected,
cells within IGFIR structures had IGFIR expression at the
plasma membrane (Figure 2a, panel i), whereas IGFIR expres-
sion was below detection in control structures (Figure 2a,
panel c).
Figure 2
Lack of acinar overgrowth in MCF-10A cells expressing kinase-dead IGFIR. (a) Differential interference contrast images of acinar structures formed 
from stable pools of MCF-10A cells infected with virus expressing empty vector (pCLXSN; panels a, b), kinase-dead (K1003A; panels d, e) and wild-
type IGFIR (panels g, h); scale bar = 80 µm. Equatorial confocal sections of pCLXSN (panel c), K1003A (panel f) and wild-type IGFIR (panel i) aci-
nar structures labeled with antibodies to the IGFIR (green) and the nuclear counterstain TO-PRO-3 (blue); scale bar = 40 µm. Cells were grown for 
20 days in media supplemented with 10 µg/ml insulin (panels a, c, d, f, g, i) or 100 ng/ml IGF-I (panels b, e, h). (b) Western blots of whole-cell 
lysates from monolayer cultures of MCF-10A cells expressing empty vector (pCLXSN), kinase-dead (K1003A) or wild-type IGFIR (IGFIR) untreated 
or treated with 50 ng/ml IGF-I (left panel) or 10 µg/ml insulin (right panel) for 5 minutes, 60 minutes or overnight (o/n) after overnight incubation in 
serum-free media. Proteins were separated by 12.5% SDS-PAGE, transferred to PVDF and incubated overnight with the indicated antibodies to sig-
naling proteins downstream of IGFIR activation.Page 5 of 13
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olayer cultures of control, K1003A and IGFIR-10A cells
treated with insulin (10 µg/ml) or IGF-I (50 ng/ml). Figure 2b
shows that IGFIR-10A cells have increased response to insu-
lin and IGF-I compared to control cells as assessed by phos-
phorylation of p70S6K at Thr389, phosphorylation of Akt at
Ser473 and phosphorylation of ERK (Thr183 and Tyr185).
Treatment of K1003A-10A cells with insulin or IGF-I did not
augment phosphorylation of downstream signaling pathways;
however, there was still some detectable phosphorylation of
Akt and ERK after insulin and IGF-I stimulation, most likely
resulting from the mixed population of infected cells.
Figure 3a shows representative, equatorial confocal sections
through acinar structures formed from control and IGFIR-10A
cells grown for 34 days and labeled with antibodies to Ki-67,
a marker of proliferation (Figure 3a, panels a, b) and cleaved
caspase-3, a marker of apoptosis (Figure 3a, panels c, d). As
expected after 34 days in culture, control cells had undergone
proliferative arrest and the few Ki-67-labeled cells were
restricted to the outer cell layer in contact with the basement
membrane (Figure 3a, panel a, arrow). In contrast, IGFIR struc-
tures had many more Ki-67 positive cells and these were
found throughout the acinar structures (Figure 3a, panel b).
We confirmed this observation by counting structures with at
least three Ki-67-labeled cells in control and IGFIR structures
from three independent experiments. After 20 days in culture,
significantly more IGFIR structures had three or more prolifer-
ating cells (75 ± 12%) compared to control structures (9 ±
2%, p < 0.01, Student's t test; Figure 3b).
In addition to increased cell proliferation, IGFIR structures dis-
played decreased cell death. Panels c, d of Figure 3a show
representative cross sections of control and IGFIR structures
labeled with antibodies to cleaved-caspase-3 after 34 days in
culture. In control structures, apoptosis and autophagy clear
the lumen of acinar structures by approximately day 10 of aci-
nar development [28]. The lumina of control structures were
hollow and any remaining cells in the lumen were undergoing
apoptosis after 34 days in culture (Figure 3a, panel c). How-
ever, the lumina of IGFIR structures remained filled with cells
at this time point, few of which had detectable cleaved cas-
pase-3 (Figure 3a, panel d).
MCF-10A acinar structures exhibit polarized organization with
the apical surface located toward the lumen and basal sur-
faces in contact with basement membrane [28-30]. We
observed polar organization of control structures with basal
deposition of laminin V (Figure 4, panel a), E-cadherin oriented
basally along lateral membranes (Figure 4, panel c) and apical
orientation of GM130, a golgi protein, in outer cells (Figure 4,
panel e, arrow). In contrast, cells within IGFIR structures
retained features of epithelial cells but their organization was
disrupted. Laminin V was generally secreted basally but there
were areas of laminin V within IGFIR structures (Figure 4,
panel b). E-cadherin was localized at sites of cell junctions
(Figure 4, panel d, arrows) but we also observed areas of
punctate E-cadherin labeling (Figure 4, panel d, arrowheads),
suggesting internalization of E-cadherin and possible changes
in cell adhesion within IGFIR structures. However, we did not
observe changes in total E-cadherin levels (data not shown).
Disruption of E-cadherin localization, with areas of both punc-
tate and labeling at cell junctions, was observed in acinar
structures formed by MCF-10A cells over-expressing both
CSF1R and CSF-1 [32]. GM130, a golgi protein apically
located in outer cells of control structures, lacked distinctive
localization and was found throughout IGFIR structures (Fig-
ure 4, panel f).
Figure 3
Increased proliferation and decreased luminal apoptosis in IGFIRstruc-tures I  struc-
tures. (a) Confocal sections of 34-day acinar structures from control 
(pCLXSN; panels a, c), and IGFIR-expressing (panels b, d) MCF-10A 
cells labeled with antibodies to the proliferative marker Ki-67 (green; 
panels a, b) or cleaved caspase-3 (green; panels c, d) and the nuclear 
counterstain TO-PRO-3 (blue). Scale bars = 50 µm. Arrows indicate a 
Ki-67-labeled cell (panel a) and a cleaved caspase-3 labeled cell (panel 
d). (b) Bar graph showing the percent of acini with three or more Ki-67-
positive cells in control and IGFIR-expressing structures. Data are 
mean ± standard deviation from three different experiments grown for 
20 days from two independently derived cell lines. At least 100 acini 
were counted in each experiment; the asterisk indicates significance, p 
< 0.01, Student's t test.Page 6 of 13
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subunit, subsequent phosphorylation and recruitment of
adapter proteins such as IRS-I and Shc, and activation of two
main signal transduction pathways: PI3K/Akt and Ras/Raf/
MAPK. Figure 5 demonstrates activation of signaling mole-
cules downstream of IGFIR. ERK phosphorylation in IGFIR-
10A cells is transient in response to insulin or IGF-I stimulation
in monolayer culture, with maximal activation after five minutes
(Figure 2b). We were consistently unable to detect phospho-
rylated ERK in IGFIR structures by immunofluorescence (data
not shown) despite being able to detect it in MCF-10A struc-
tures over-expressing Raf (Dr Gray Pearson, personal commu-
nication). However, IGFIR activation of MAPK is likely to be
weak compared to over-expressed Raf.
In response to growth factors, Akt, downstream of PI3K, is
phosphorylated at two sites, Thr308 and Ser473, and contrib-
utes to growth and survival signaling by phosphorylating
downstream targets such as mTOR, BAD (Bcl-xL/Bcl-2-asso-
ciated death promoter homolog) and the forkhead transcrip-
tion factors (reviewed in [37,38]). We analyzed the role of Akt
activation in survival signaling in IGFIR structures by labeling
with antibodies specific for Akt phosphorylated on Ser473,
indicative of Akt activation [39]. In control structures, we
observed phosphorylated Ser473 of Akt only in cells in con-
tact with the basement membrane and only in early stages of
acinar development (Figure 5, panel a). However, phosphor-
ylated Akt was observed throughout IGFIR structures even at
late time points (Figure 5, panel b), suggesting a critical role
for Akt signaling in the growth and survival signaling of IGFIR
acinar structures. We used antibodies specific for mTOR
phosphorylated on Ser2448 to monitor mTOR activation in
IGFIR structures. Although the identity of the kinase responsi-
ble for phosphorylation of Ser2448 following growth factor
stimulation is unclear, Ser2448 phosphorylation is generally
accepted to be indicative of mTOR activation [40-43]. We
observed phosphorylation of Ser2448 of mTOR in cells
throughout IGFIR structures (Figure 5, panel d) but not in
those of control structures (Figure 5, panel c).
Figure 4
Disrupted apico-basal polarity of IGFIR structures. Equatorial confocal sections of 20-day control (pCLXSN, panels a, c, e) and IGFIR structures 
(panels b, d, f) labeled with antibodies to laminin V (red; panels a, b), E-cadherin (red; panels c, d) and Golgi matrix protein of 130 kDa (GM130; 
green; panels e, f) and the nuclear counterstain TO-PRO-3 (blue). Arrows indicate localization of E-cadherin at cell-cell junctions (panel d) and apical 
localization of GM130 in control structures (panel e). Arrowheads show sites of punctate E-cadherin labeling (panel d). Scale bars = 50 µm.
Figure 5
Induction of Akt signaling in IGFIR structures. Equatorial confocal sec-
tions of 34-day control (pCLXSN, panels a, c) and IGFIR acinar struc-
tures (panels c, d) labeled with phosphospecific antibodies to Akt- 
[S473] (green; panels a, b) and mammalian target of rapamycin 
(mTOR)- [S2448] (green; panels c, d) and the nuclear counterstain 
TO-PRO-3 (blue). Scale bars = 50 µm.Page 7 of 13
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MAPK pathways in promoting proliferation and survival signal-
ing in IGFIR structures by pharmacological inhibition of PI3K
with 50 µM LY294002 [44,45], MAP kinase kinase (MEK)
with 10 µM UO126 [46], and mTOR with 20 to 100 nM
rapamycin [47,48]. IGFIR-10A and control cells were grown in
three-dimensional cultures with standard growth medium for
three days to allow initiation of acinar development, and then
inhibitors were maintained in the growth medium during all
subsequent media changes for an additional 12 to 15 days
(see Materials and methods). Figure 6a shows confocal sec-
tions of IGFIR (panels b, c, e, f, h, i) and control structures
(panels a, d, g) grown in the presence of UO126 (panels a-c),
LY294002 (panels d-f), and rapamycin (panels g-i). Cultures
were labeled with the nuclear counterstain TO-PRO-3 and
antibodies to Ki-67 (Figure 6a, panels a, b, d, e, g, h) and
cleaved caspase-3 (panels c, f, i).
Inhibition of MEK with 10 µM UO126 prevented any signifi-
cant development of IGFIR structures. Any structures present
Figure 6
Inhibition of PI3K or MEK but not mTOR disrupts IGFIR acinar development. (a) Confocal sections of 20-day control (pCLXSN, panels a, d, g) and 
IGFIR (panels b, c, e, f, h, i) acinar structures grown in the presence of the MEK inhibitor, UO126 (10 µm; panels a-c), the PI3K inhibitor LY294002 
(50 µm; panels d-f) and the mTOR inhibitor rapamycin (40 nM; panels g-i). Fixed structures were labeled with the nuclear counterstain TO-PRO-3 
(blue) and with antibodies to Ki-67 (green; panels a, b, d, e, g, h) or cleaved caspase-3 (green; panels c, f, i). Scale bars = 50 µm. The arrow in panel 
b indicates Ki-67-labeled cells. (b) Whole-cell lysates of 16d IGFIR acinar structures were isolated after overnight serum starvation followed by 30 
minute pretreatment with DMSO (vehicle) or 40 nM rapamycin and subsequent 30-minute incubation with 10 µg/ml insulin. Lysates were immuno-
precipitated with antibodies to p70S6K, separated by 12.5% SDS-PAGE, transferred to PVDF and immunoblotted with antibodies to p70S6K or 
phosphospecific antibodies to Thr389 of p70S6K as indicated.Page 8 of 13
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els b, c). There was no apparent lumen formation, but we were
able to detect both Ki-67 labeled cells (Figure 6a, panel b,
arrow) and cleaved caspase-3 labeled cells (Figure 6a, panel
c) in IGFIR structures with UO126 treatment; 10 µM UO126
is not generally cytotoxic as no effect was observed on the
development of control structures (Figure 6a, panel a). The
lack of appreciable structure formation suggests an important
role for MAPK activation in early stages of IGFIR structure
development.
Inhibition of PI3K with 50 µM LY294002 had a similar effect
on IGFIR structure formation: any structures present appeared
as clusters of cells (Figure 6a, panels e, f). There was no
apparent lumen formation but, unlike with UO126 treatment,
we did not detect any Ki-67-labeled cells (Figure 6a, panel e).
Although rare, we could detect cells undergoing apoptosis in
cultures treated with 50 µM LY294002 as assessed by
cleaved-caspase-3 labeling (Figure 6a, panel f); 50 µM
LY294002 was not generally cytotoxic, as no effect on control
structure formation was observed (Figure 6a, panel d). These
results highlight the importance of PI3K and MEK activation in
early stages of IGFIR structure formation and suggest that
IGFIR-10A cells have become physiologically dependent on
IGFIR signaling.
Three-dimensional cultures of MCF-10A cells expressing myr-
istoylated Akt formed large, partially filled structures with
increased proliferation at early stages of growth [47]. Rapamy-
cin (5 and 20 nM) prevented overgrowth induced by Akt acti-
vation, suggesting a critical role for mTOR in mediating the
growth promoting effects of Akt [47]. To determine the contri-
bution of raptor/mTOR signaling following Akt activation in
IGFIR structures, we treated developing acinar structures with
rapamycin [48]. Unexpectedly, rapamycin had no apparent
effect on the growth of IGFIR structures; IGFIR structures
remained large and misshapen in the presence of 40 nM
rapamycin (Figure 6a, panels h, i) and in concentrations up to
100 nM (data not shown). In addition, we consistently
observed Ki-67 positive cells throughout the structures,
including cells lacking contact with the basement membrane
(Figure 6a, panel h). Similar to untreated or DMSO-treated
(data not shown) IGFIR structures, few apoptotic cells were
observed (Figure 6a, panel i). Rapamycin did not affect the for-
mation of control structures (Figure 6a, panel g) but was effec-
tive in inhibiting insulin-induced phosphorylation of Thr389 of
p70S6 kinase after insulin-induced stimulation of day 16
IGFIR acinar structures (Figure 6b). These results suggest
that while Akt signaling is upregulated in IGFIR structures, the
hyperproliferation phenotype and anti-apoptotic signaling
were not mediated solely through Akt activation of raptor/
mTOR signaling.
Discussion
Breast cancer is a progressive disease: pre-invasive lesions,
such as atypical hyperplasias and carcinomas in situ, have
increased cell numbers and filled and enlarged mammary alve-
oli that remain contained by basement membrane proteins;
cancerous cells overcome the constraints of the basement
membrane and invade the surrounding connective tissue in
invasive stages; advanced, metastatic stages are character-
ized by cancer cells leaving the breast, usually via the lym-
phatic system, and invading other organs [49]. Three basic
processes are abnormally regulated in this progression: cellu-
lar proliferation, survival signaling and invasion. Dysregulation
of these processes are features of all cancers and can be
recapitulated with in vitro models [50]. Recapitulation of nor-
mal mammary tissue with model systems, such as three-
dimensional cultures of breast epithelial cells, provides an
attractive system with which to determine the effect of onco-
genic disruption of proliferation, survival signaling and invasion
on breast epithelial cell biology without additional complica-
tions such as inflammatory and hormone signaling [25].
Our data support and extend those reported in a recent paper
by Irie and colleagues [26] demonstrating isoform specific
effects of knocking down Akt1 or Akt2 in IGFIR acinar struc-
tures. The general morphological features of IGFIR-10A cells
grown on matrigel (increased proliferation, decreased apopto-
sis, misshapen and filled acinar structures) are similar to those
observed by Irie and colleagues with cells grown on a 50:50
mixture of Matrigel/collagen. We showed that IGFIR struc-
tures had disrupted organization while retaining epithelial
characteristics: laminin V secretion basally as well as within
IGFIR structures; GM130 localization no longer apically ori-
ented; and disruption of E-cadherin localization but no
changes in total amounts of E-cadherin. These results support
the conclusion by Irie and colleagues that IGFIR cells have not
undergone a complete epithelial-mesenchymal transition. In
addition, although not discussed in their paper, they show dis-
organized labeling of α 6-integrin that corresponds with what
we observed with laminin V labeling of IGFIR structures.
Knockdown of both Akt1 and Akt2 resulted in acini that were
severely disrupted, supporting our data showing that inhibition
of PI3K with LY294002 prevents significant acinar formation
of IGFIR but not control cells and confirms the importance of
both isoforms for the IGFIR acinar phenotype. In addition, Irie
and colleagues showed that knock-down of Akt2 prevented
overgrowth of IGFIR structures and resulted in slightly larger
but otherwise normal acinar structures. Knock-down of Akt1 in
IGFIR cells resulted in a dramatic phenotypic change: invasive
structures, epithelial-mesenchymal transition and increased
migration in a trans-well assay. These changes resulted from
loss of inhibition of ERK by Akt1.
Acinar structures formed from MCF-10A cells expressing a
variety of oncogenes have several characteristic features:
increased proliferation, decreased apoptosis, and filledPage 9 of 13
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MCF-10A cells resulted in highly proliferative, multi-acinar
structures with filled lumina [29]. These structures retained
certain features of epithelial cells, such as secretion of base-
ment membrane proteins, but lacked the apical-basal polar
organization typical of MCF-10A cells. Constitutive activation
of the CSF-1 receptors through an activated receptor con-
struct or via autocrine production of CSF-1 by MCF-10A cells
also resulted in highly proliferative acinar structures, yet they
lacked the multi-acinar organization of ErbB2 structures and
instead exhibited Src-dependent disruption of cell-cell junc-
tions such that individual cells were capable of dissociating
from an acinus [35]. Over-expression of activated Akt1 in
MCF-10A cells resulted in enlarged acini that were only mod-
erately filled; apoptosis was not completely inhibited as both
viable and apoptotic cells could be found within the lumina and
proliferation was enhanced only in early days of acinar devel-
opment [47]. Rapamycin treatment of Akt1 structures pre-
vented the increased cell size, overgrown, and filled
structures, indicating that Raptor/mTOR signaling was medi-
ating the effects of Akt1 in these cells [47]. Finally, expression
of human growth hormone in MCF-10A cells also resulted in
enlarged, disorganized and filled acinar structures with
increased proliferation and decreased apoptosis [36]. Growth
hormone acting through IGF-I is essential for proper mammary
gland development [4,51-53].
Acinar structures formed from IGFIR-10A cells display notable
similarities and differences with each of these phenotypes.
First, IGFIR structures displayed increased proliferation as
assessed by Ki-67 expression, similar to ErbB2, CSF1R and
growth hormone structures. However, the increase in prolifer-
ation in IGFIR structures occurs during both early (data not
shown) and late stages of acinar development, as opposed to
structures formed from over-expression of Akt1 in which pro-
liferation is seen only in early stages. Second, IGFIR structures
had decreased apoptosis, assessed by cleaved caspase-3
expression, as would be expected from their filled lumina, a
feature that is similar to ErbB2, CSF1R, Akt1 and growth hor-
mone structures. The anti-apoptotic effects could occur
through direct actions on apoptotic signaling molecules, such
as through suppression of Bim [45] or represent cross-talk
between the Ras/Raf/MAPK and PI3K/Akt signaling pathways
in these cells. Third, IGFIR structures retain some features of
epithelial cells, such as secretion of certain basement mem-
brane proteins, but, similar to ErbB2 and growth hormone-
expressing MCF-10A cells, they appear to have disrupted
apico-basal polar organization. It is this last feature that may
distinguish the phenotype of IGFIR, ErbB2 and growth hor-
mone-expressing structures from that seen with simultaneous
expression of proliferative and anti-apoptotic proteins: expres-
sion of both cyclin D1 and Bcl-xL, or human papilloma virus 16
E7 and Bcl2, results in only slightly enlarged and modestly
filled acini that retain apico-basal polarity [30].
Over-expression of IGFIR in a breast cancer cell line, MCF-7,
and growth on Matrigel resulted in enlarged structures as a
result of aggregation of cells due to increased cell-cell adhe-
sion via E-cadherin [54]. Addition of 20 ng/ml IGF-I stimulated
aggregation of MCF-7 cells even in the absence of over-
expressed IGFIR. The ability of MCF-7/IGFIR cells to grow for
prolonged periods in this system (20 days) was enhanced with
increasing levels of receptor expression. These results high-
light several important differences between MCF-7 and MCF-
10A cells used to determine the effect of IGFIR over-expres-
sion. First, MCF-10A cells are a spontaneously immortalized
cell line and though they have genotypic changes (such as
myc amplification and loss of p16) that may make them more
susceptible to phenotypic changes resulting from introduction
of an oncogene, they do not form colonies in soft agar or
tumors in nude mice, unlike MCF-7 cells. Second, unlike MCF-
10A cells, MCF-7 cells express the estrogen receptor. Given
the cross-talk between estrogen receptor and IGFIR signaling,
this may represent an important difference in the ability of
IGFIR over-expression to promote cell aggregation in one sys-
tem and stimulate proliferation and survival signaling in
another, although it is not clear to what extent proliferative and
survival signaling were stimulated in structures formed from
MCF-7 cells over-expressing the IGFIR.
Dependence on the continued signaling of a mutated or over-
expressed oncogene may be exploited for targeted cancer
therapies [55]. Antisense oligonucleotides to Ki-ras
decreased growth of pancreatic cell lines expressing mutated
but not wild-type Ki-ras [56]. Inhibition of MEK selectively
affected cells and tumors with mutated BRAF compared to
wild-type or RAS mutant cells due to unique ERK-dependent
cyclinD1 expression in BRAF mutant cells [57]. Rather than
induce normal acinar structures, inhibition of PI3K or MEK with
LY294002 and UO126, respectively, completely disrupted
acinar development of IGFIR structures. No detectable effect
of PI3K or MEK inhibition was observed on development of
control acini, suggesting that MCF-10A cells over-expressing
the IGFIR have become physiologically dependent on IGFIR
signaling and that chemotherapeutics targeted to the IGFIR
may selectively affect cancerous cells with elevated IGFIR sig-
naling.
Rapamycin prevented acinar morphology associated with
over-expression of activated Akt1 and mutated PI3K [47,58].
Although Akt is activated in IGFIR structures, rapamycin was
not effective in preventing the growth of IGFIR structures,
despite its ability to prevent insulin-induced phosphorylation at
Thr389 of p70S6K (Figure 6b). Several possible reasons exist
for this apparent discrepancy. First, signaling via raptor/mTOR
may not be a primary pathway driving proliferation and survival
signaling in IGFIR structures. Activation of signaling pathways
in addition to Akt/mTOR may be sufficient to override the con-
tribution of raptor/mTOR to proliferation and survival signaling.
Second, rapamycin treatment may inhibit the negative feed-Page 10 of 13
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[59,60]). Our unpublished data suggests that this is at least
partly responsible. Third, the recent paper by Irie and col-
leagues [26] showed that knock-down of Akt2 but not Akt1 in
IGFIR-10A cells resulted in slightly larger, but otherwise nor-
mal acinar structures. Since rapamycin inhibited the abnormal
growth of Akt1-10A cells but does not inhibit IGFIR-10A cells,
this may represent additional isoform specific signaling differ-
ences, with Akt1 potentially selectively activating raptor/
mTOR. The lack of effectiveness of rapamycin in preventing
IGFIR acinar phenotype may have important implications on
the usefulness of mTOR as a target for breast cancer thera-
peutics and suggests that rapamycin analogues may be best
used in combination with other therapeutics [61,62].
Epithelial cell proliferation, survival signaling and invasion of
the surrounding stromal tissue are critical processes for nor-
mal mammary gland development, suggesting a strong link
between normal mammary development and pathogenesis of
breast cancer. The increased proliferative and survival signal-
ing we observed in IGFIR structures are compatible with the
established role of IGF-I signaling in mammary gland develop-
ment. IGFIR knockout mice die shortly after birth due to respi-
ratory failure, but transplanted embryonic mammary buds from
IGFIR knockout mice in syngeneic recipients showed
decreased proliferation of cap cells in the terminal end buds
and decreased branching and extension of ducts into the fat
pad [3]. Similarly, IGF-I knock-out mice had fewer terminal end
buds and decreased ductal branching [4,5]. Mice expressing
a truncated human IGF-I that has reduced affinity for insulin-
like growth factor binding proteins had persistent, progressive
ductal hypertrophy after several rounds of lactation, decreased
natural involution and three-fold increase in the incidence of
spontaneous mammary tumors [8,9]. Other growth factors
involved in mammary gland development have also been impli-
cated in the pathogenesis of breast cancer. For example, the
tyrosine kinase receptor ErbB2, amplified in 30% of breast
cancers, is important for early steps in terminal end bud forma-
tion and ductal extension into the mammary fat pad of mice,
and MCF-10A cells expressing activated ErbB2 form multi-
lobed, filled acinar structures [29,63,64].
Conclusion
Several factors promoting or affecting breast cancer patho-
genesis, such as Her2/neu, estrogen and progesterone recep-
tors, E-cadherin, vascular endothelial growth factor, and
BRCA1 have been identified and are useful as prognostic indi-
cators or therapeutic targets [65-67]. In this work we demon-
strate that increased IGFIR signaling promotes morphological
and growth phenotypes reminiscent of early pathological
changes in breast cancer. Our results extend the well-known
importance of IGFIR activation for proliferative and survival sig-
naling. This model system will be useful for identifying factors
that augment IGFIR signaling to enhance breast cancer pro-
gression as well as for characterizing novel chemotherapeu-
tics working through the IGFIR signaling pathway.
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